Register entry
- Registered sites
- 0
- Active NDC listings
- 8
- Labeller names
- 2
- Live patents
- 8
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
88 active NDC listings: 8 human prescription drug. By marketing category: NDA 7, BLA 1.
| Dosage form | NDCs |
|---|---|
| tablet | 4 |
| powder | 2 |
| suspension | 2 |
| Route | NDCs |
|---|---|
| oral | 7 |
| intracerebral | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| ptc therapeutics, inc. | 6 |
| ptc therapeutics inc. | 2 |
Exclusivity
Patents and exclusivities
8| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 11072614 | SEPHIENCEsepiapterin | substance | Apr 2038 |
| 11752154 | SEPHIENCEsepiapterin | product | Sept 2038 |
| 12213982 | SEPHIENCEsepiapterin | use | Sept 2038 |
| 12257252 | SEPHIENCEsepiapterin | use | Mar 2042 |
| Product | Exclusivity | Until |
|---|---|---|
| SEPHIENCESEPIAPTERIN | ODE-542 Orphan drug | Jul 2032 |
Catalogue
Marketed products
8| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| EMFLAZA | deflazacort | tablet, oral | 52856-501NDA |
| EMFLAZA | deflazacort | tablet, oral | 52856-502NDA |
| EMFLAZA | deflazacort | tablet, oral | 52856-503NDA |
| EMFLAZA | deflazacort | tablet, oral | 52856-504NDA |
| EMFLAZA | deflazacort | suspension, oral | 52856-505NDA |
| KEBILIDI | eladocagene exuparvovec-tneq | suspension, intracerebral | 52856-601BLA |
| Sephience | sepiapterin | powder, oral | 52856-201NDA |
| Sephience | sepiapterin | powder, oral | 52856-301NDA |
Compare
Other companies listing deflazacort
- Aucta Pharmaceuticals, Inc.2 sites · 8 NDC
- Amneal Pharmaceuticals NY LLC0 sites · 337 NDC
Enquiry
Common questions
- Is PTC Therapeutics, Inc. FDA approved?
- PTC Therapeutics, Inc. holds no registered establishment of its own; 8 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does PTC Therapeutics, Inc. make?
- 8 products are listed under PTC Therapeutics, Inc. in the openFDA NDC Directory, most often as tablet; powder; suspension. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.